title: Circulating soluble Fas levels and risk of ovarian cancer.
abstract: BACKGROUND
  Dysregulation of apoptosis, specifically overexpression of soluble Fas (sFas), has been proposed to play a role in the development of ovarian cancer. The main objective of the present study was to evaluate serum sFas as a potential biomarker of ovarian cancer risk.
  
  
  METHODS
  The association between serum sFas levels and the risk of ovarian cancer was examined in a case-control study nested within three prospective cohorts in New York (USA), Umeå (Sweden), and Milan (Italy). Case subjects were 138 women with primary invasive epithelial ovarian cancer diagnosed between 2 months and 13.2 years after the initial blood donation. Control subjects were 263 women who were free of cancer, and matched the case on cohort, menopausal status, age, and enrollment date. Serum sFas levels were determined using a quantitative sandwich enzyme immunoassay.
  
  
  RESULTS
  Serum sFas levels were similar in women subsequently diagnosed with ovarian cancer (median, 6.5 ng/mL; range, 4.4-10.2) and in controls (median, 6.8 ng/mL; range, 4.5-10.1). Statistically significant trends of increasing serum sFas with age were observed among cases (r = 0.39, p < 0.0001) and controls (r = 0.42, p < 0.0001). Compared to women in the lowest third, women in the highest third of serum sFas were not at increased risk of ovarian cancer after adjustment for potential confounders (odd ratio (OR), 0.87; 95% confidence interval (CI), 0.42-1.82).
  
  
  CONCLUSIONS
  The results suggest that serum sFas may not be a suitable marker for identification of women at increased risk of ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA. akhmea01@med.nyu.edu
authors.forename: Arslan
authors.initials: A
authors.lastname: Akhmedkhanov
authors.forename: Eva
authors.initials: E
authors.lastname: Lundin
authors.forename: Seth
authors.initials: S
authors.lastname: Guller
authors.forename: Annekatrin
authors.initials: A
authors.lastname: Lukanova
authors.forename: Andrea
authors.initials: A
authors.lastname: Micheli
authors.forename: Yuehong
authors.initials: Y
authors.lastname: Ma
authors.forename: Yelena
authors.initials: Y
authors.lastname: Afanasyeva
authors.forename: Anne
authors.initials: A
authors.lastname: Zeleniuch-Jacquotte
authors.forename: Vittorio
authors.initials: V
authors.lastname: Krogh
authors.forename: Per
authors.initials: P
authors.lastname: Lenner
authors.forename: Paola
authors.initials: P
authors.lastname: Muti
authors.forename: Sabina
authors.initials: S
authors.lastname: Rinaldi
authors.forename: Rudolf
authors.initials: R
authors.lastname: Kaaks
authors.forename: Franco
authors.initials: F
authors.lastname: Berrino
authors.forename: Göran
authors.initials: G
authors.lastname: Hallmans
authors.forename: Paolo
authors.initials: P
authors.lastname: Toniolo
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood*; D011446:Prospective Studies; D019014:fas Receptor / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D019014:fas Receptor